✦ LIBER ✦

Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study

✍ Scribed by Roger J Laham; Nicholas A Chronos; Marilyn Pike; Mark E Leimbach; James E Udelson; Justin D Pearlman; Roderic I Pettigrew; M.J Whitehouse; Carl Yoshizawa; Michael Simons

Book ID: 119541847
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 339 KB
Volume: 36
Category: Article
ISSN: 1558-3597
DOI: 10.1016/s0735-1097(00)00988-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

SAFETY AND TOLERABILITY OF GLIAL GROWTH

SAFETY AND TOLERABILITY OF GLIAL GROWTH FACTOR 2 IN PATIENTS WITH CHRONIC HEART FAILURE: A PHASE I SINGLE DOSE ESCALATION STUDY

✍ Lenihan, Daniel J.; Anderson, Sarah; Geisberg, Carrie; Caggiano, Anthony; Eisen, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 151 KB

The insulin-like growth factor-I recepto

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study

✍ Molife, L R; Fong, P C; Paccagnella, L; Reid, A H M; Shaw, H M; Vidal, L; Arkena 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 469 KB